Results 161 to 170 of about 76,053 (241)

A Pharmacogenomic Basis for Tolerance of 5-Fluorouracil Following Early, Severe Toxicity from Capecitabine in a CDA Ultrarapid Metabolizer Colon Cancer Patient: A Case Report. [PDF]

Cancer Manag Res
Mazhindu TA, Chikwambi Z, Matsikidze E, Grimes KV, Borok MZ, Ndlovu N, Masimirembwa C, Consortium for Genomics and Therapeutics in Africa.   +7 more
europepmc   +1 more source

TBKBP1 induces capecitabine resistance through negative regulation of type I interferon pathway in triple-negative breast cancer. [PDF]

Oncogene
Wu WY, Yang YS, Andriani L, Xie YF, Di GH, Shao ZM, Li JJ.   +6 more
europepmc   +1 more source

Impact of Thiazides and Fluoropyrimidines Interaction on Myelotoxicity and Other Adverse Events in Real-World Practice: A Retrospective Cohort Study. [PDF]

Cancer Med
Ronda-Roca G, Porcel-Maleno J, Lobo-Palomar M, Centeno-Soto G, Ruiz-Casado A, Ruiz-Antorán B.   +5 more
europepmc   +1 more source

Setting the record straight: Activity of gemcitabine monotherapy for breast cancer - Reply [PDF]

, 2004
Heinemann, Volker
core   +1 more source

A review of the current evidence for maintenance therapy in gastric cancer. [PDF]

Front Pharmacol
Han X, Zhang Y, Fan Q, Yu J, Lv L, Li Y, Hou L.   +6 more
europepmc   +1 more source

Preoperative Chemoradiotherapy with Tegafur-Uracil, Capecitabine, or 5-Fluorouracil/Leucovorin for Rectal Cancer in an Asian Cohort: A Real-World Comparison from the Pre-TNT Era. [PDF]

Curr Oncol
Dai KY, Chen FY, Liu CK, Lin J, Liu SH.
europepmc   +1 more source

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer. [PDF]

Clin Cancer Res
Jhaveri K, Loi S, Hamilton E, Schmid P, Anders CK, Testa L, Wildiers H, Tseng LM, Lu YS, Park YH, Im SA, Chen SC, Young RR, Lloyd C, Wrona M, Zhang C, Carroll D, André F.   +17 more
europepmc   +1 more source

Safety and efficacy of PEG-rhG-CSF as primary prophylaxis for neutropenia in gastrointestinal cancer patients receiving combination chemotherapy including oral agents: a prospective, exploratory, non-randomized controlled study. [PDF]

Front Oncol
Wang H, Zhang X, Du Y, Liu M, Ma N, Gao Y, Wang M, Cai L, Feng T, Yang S, Hu W, Zhang G, Zhao J.   +12 more
europepmc   +1 more source

Recurrent hyperammonemic encephalopathy in a breast cancer patient receiving capecitabine therapy: a case report and literature review. [PDF]

Front Pharmacol
Mu Y, Li Q, Kong J, Zhao Y.
europepmc   +1 more source

Survival outcomes and prognostic value of nutritional and inflammatory markers in third-line treatment of metastatic pancreatic cancer. [PDF]

Front Oncol
Vidulin J, Ondruš D, Pöršök Ś, Kráčalíková M, Ušáková V, Šuták K, Miškovičová M, Kizeková M, Fremal M, Pisáková J, Kecskés I, Lešková J, Bystrický B.   +12 more
europepmc   +1 more source